AML Archives | Be Korea-savvy

Home / Posts tagged AML

Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML After Completing Interim Analysis

Lugano, Switzerland and San Diego, USA, July 2 (Korea Bizwire) – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare diseases products, and MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announce that an interim futility analysis of the ongoing Phase 3 [...]

$The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, Including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay$

The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, Including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay

SAN DIEGO, Dec. 5 (Korea Bizwire) — For twenty-five years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. The LeukoStrat® CDx FLT3 Mutation Assay may now be used as an aid in the assessment of AML patients for treatment with XOSPATA® (gilteritinib) [...]